Clearmind Medicine Inc. Common Shares (CMND)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earnings power, honest book value, and a margin of safety. Clearmind fails most of those tests. It is a clinical-stage psychedelic-medicine company with revenue growth listed as N/A. At the 2026-10-13 close of $6.23, the market cap is only $1.9M. FairStock’s calculations show a negative P/E of -0.11 and a P/B of 1.03; a P/B near one might sound comforting, but for a pre-revenue biotech book value is mostly cash that is being consumed. Trailing free cash flow is -$7.8M, and the FCF yield is -410.2% against that tiny market cap. That is not a business funding itself; it is a business that must keep raising capital. Returns are terrible: ROE -106.98%, ROCE -53.08%. The balance sheet has low debt with D/E of 0.14, but low debt does not help when cash burn is so large relative to market value. The Piotroski F-Score is 0/9 and Altman Z-Score is -1.68, signs of deep financial weakness. There is no computed Lynch category because only 0 years of results are filed. The 52-week range of $0.52 to $48.00 shows extreme speculation. The company may have scientific optionality in MEAI for alcohol use, obesity, and metabolic disorders, but I cannot identify a competitive moat, consistent revenue, or earnings. Growth is unproven and dependent on trial outcomes and financing. I would need a much larger margin of safety and evidence of commercial progress before calling this a sound value investment.

In plain English: Clearmind Medicine is a clinical-stage company trying to develop psychedelic-based treatments for alcohol use, eating, and metabolic disorders. The business looks weak: no revenue growth is shown, it is losing money, and it burns cash. At the 2026-10-13 close of $6.23, the price looks speculative rather than supported by current profits or cash flow.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer